Antiplatelet agents and randomized trials

Reviews in Neurological Diseases

Volumn 4, Issue 4, 2007, Pages 177-183

  Diener, Hans Christoph ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Antiplatelet drugs; Aspirin; Clopidogrel; Dipyridamole; Stroke; Stroke prevention

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL;

ANTICOAGULANT THERAPY; ARTERY DISEASE; BLEEDING; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG MECHANISM; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; REVIEW; RISK FACTOR; SECONDARY PREVENTION; TRANSIENT ISCHEMIC ATTACK;

ASPIRIN; DIPYRIDAMOLE; DRUG THERAPY, COMBINATION; HUMANS; ISCHEMIC ATTACK, TRANSIENT; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; STROKE; TICLOPIDINE;

EID: 37549049383     PISSN: 15452913     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Kolominsky-Rabas PL, Heuschmann PU, Marschall D, et al. Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen Stroke Project. Stroke. 2006;37:1179-1183.
2. Albers GW. Choice of endpoints in antiplatelet trials. Which outcomes are most relevant to stroke patients? Neurology. 2000;54:1022-1028.
3. Petty GW, Brown RD, Whisnant JP, et al. Ischemic stroke subtypes. A population-based study functional outcome, survival and recurrence. Stroke. 2000;31:1062-1068.
4. Hankey GJ, Warlow CP, Slattery J. The prognosis of transient ischaemic attacks. J Neurol. 1990;237:142.
5. Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA. 2000;284:2901-2906.
6. Johnston SC, Rothwell PM, Nguyen-Huynh MN, Giles MF, et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet. 2007;369:283-292.
7. Rothwell PM, Warlow CP. Timing of TIAs preceding stroke: time window for prevention is very short. Neurology. 2005;64:817-820.
8. Weimar C, Roth MP, Zillessen G, et al. German Stroke Data Bank Collaborators. Complications following acute ischemic stroke. Eur Neurol. 2002;48:133-140.
9. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;524:71-86.
10. Born G, Patrono C. Antiplatelet drugs. Br J Pharmacol. 2006;147(suppl 1):S241-S251.
11. Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA. 2007;297:2018-2024.
12. Eisert W. Dipyridamole. In: Michelsen A, ed. Platelets. Oxford: Academic Press; 2002:803-815.
13. The ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006;367:1665-1673.
14. Diener H, Bogousslavsky J, Brass LM, et al; on behalf of the MATCH Investigators. Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): Study design and baseline data. Cererbrovasc Dis. 2004;17:253-261.
15. Savi P, Nurden P, Nurden AT, et al. Clopidogrel: a review of its mechanism of action. Platelets. 1998;9:251-255.
16. Lotrionte M, Biondi-Zoccai GG, Agostoni P, et al. Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2007;100:1199-1206.
17. Kennedy J, Hill MD, Ryckborst KJ, et al; FASTER Investigators. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol. 2007;6:961-969.
18. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353:2373-2383.
19. Patrono C, Roth GJ. Aspirin in ischemic cerebrovascular disease. Stroke. 1996;27:756-760.
20. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med. 1991;325:1261-1266.
21. UK-TIA Study Group. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry. 1991;54:1044-1054.
22. Algra A, van Gijn J. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry. 1999;65:255.
23. Diener HC, Cuhna L, Forbes C, et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1-13.
24. Topol E, Easton D, Harrington R, et al; on behalf of the Blockade of the Glycoprotein IIIb/IIIa Receptor to Avoid Vascular Occlusion (BRAVO) Trial Investigators. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation. 2003;108:16-23.
25. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation. 2006;113:e409-e449.
26. Diener HC, Allenberg JR, Bode C, et al. Recommendations of the German Neurological Society and the German Stroke Society for Primary and Secondary Stroke Prevention: update 2007 [in German]. Akt Neurol. 2007;34:8-12.
27. Hass WK, Easton JD, Adams HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke. N Engl J Med. 1989;321:501-507.
28. Gent M, Blakely JA, Easton JD, et al. The Canadian American ticlopidine study (CATS) in thromboembolic stroke. Lancet. 1989;1:1215-1220.
29. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
30. Ringleb P, Bhatt D, Hirsch A, et al; Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events Investigators. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke. 2004;35:528-532.
31. Bhatt DL, Marso SP, Hirsch AT, et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol. 2002;90:625-628.
32. Bhatt D, Chew D, Hirsch A, et al. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation. 2001;103:363-368.
33. Bhatt D, Foody J, Hirsch A, et al. Complementary, additive benefit of clopidogrel and lipid-lowering therapy in patients with atherothrombosis. J Am Coll Cardiol. 2000;35(suppl A):326.
34. Diener HC, Ringleb PA, Savi P. Clopidogrel for secondary prevention of stroke. Expert Opin Pharmacother. 2005;6:755-764.
35. Diener H, Bogousslavsky J, Brass L, et al; on behalf of the MATCH Investigators. Acetylsalicylic acid on a background of clopidogrel in high-risk patients randomised after recent ischaemic stroke or transient ischaemic attack: The MATCH trial results. Lancet. 2004;364:331-334.
36. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706-1717.
37. Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49:1982-1988.
38. Diener HC, Forbes C, Riekkinen PJ, et al; and the ESPS Group. European Stroke Prevention Study 2: Efficacy and safety data. J Neurol Sci. 1997;151(supp1):S1-S77.
39. The ESPS Group. The European Stroke Prevention Study (ESPS). Principal endpoints. Lancet. 1987;2:1351-1354.
40. Diener HC. Modified-release dipyridamole combined with aspirin for secondary stroke prevention. Aging Health 2005;1:19-26.
41. Diener HC, Sacco R, Yusuf S. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovasc Dis. 2007;23:368-380.
42. Müller TH, Su CA, Weisenberger H, et al. Dipyridamole alone or combined with low dose acetylsalicyclic acid inhibits platelet aggregation in human whole blood ex vivo. Br J Clin Pharmacol. 1990;30:179-186.